16305 36TH AVENUE N, MINNEAPOLIS, MN
Market cap: $4.7B (12/18/2025)
Price: $101.16
Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Material Contracts, Other Events
Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus